CEA-Scan gets unanimous panel recommendation:
This article was originally published in Clinica
Immunomedics' CEA-Scan was unanimously recommended for approval by the US FDA's Medical Imaging Drugs Advisory Panel on February 16th. The recommendation covers use in colorectal cancer, but the marker also has applications in lung, breast, pancreatic, uterine and ovarian cancer. The Oncologic Drugs Panel had referred the data after its October 1994 meeting. It also expressed concern at a lack of evidence for improved outcome with CEA-Scan (see Clinica No 678, p 19).